Patients with follicular lymphoma (FL) frequently require multiple treatments during their
disease course; however, survival based on lines of treatment remains poorly described in …

Disease overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …

Disease overview Follicular lymphoma is generally an indolent B cell lymphoproliferative
disorder of transformed follicular center B cells. Follicular lymphoma (FL) is characterized by …

Disease overview: Follicular lymphoma (FL) is generally an indolent B‐cell
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …

Abstract Disease Overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …

Background The natural history of follicular lymphoma is believed not to have changed over
the last 30 years. Median survivals have ranged from 7 to 10 years, and the disease is …

Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine,
and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine …

Background Because follicular lymphoma (FL) patients have heterogeneous outcomes, the
FL international prognostic index (FLIPI) was developed to risk-stratify patients and to predict …

The Follicular Lymphoma International Prognostic Index (FLIPI) was developed to predict
prognosis of patients with follicular lymphoma (FL). However, it was based on different …

Purpose Patients with follicular lymphoma (FL) registered in the F2-study and initially
managed without treatment were analyzed to describe the presentation and outcome of a …